184368-70-5

Basic information

• Product Name: trans-2,6-Dimethylpiperidin-4-one,N-BOCprotected
• Synonyms: trans-2,6-Dimethylpiperidin-4-one,N-BOCprotected;trans-2,6-Dimethyl-4-oxo-piperidine-1-carboxylic acid tert-butyl ester
• CAS NO: 184368-70-5
• Molecular Formula: C7H13NO
• Molecular Weight: 127.18422
• Mol File: 184368-70-5.mol

Chemical Properties

• Boiling Point: 308.2±35.0 °C(Predicted)
• Appearance: /
• Density: 1.027±0.06 g/cm3(Predicted)
• PKA: -1.46±0.60(Predicted)
• CAS DataBase Reference: trans-2,6-Dimethylpiperidin-4-one,N-BOCprotected(CAS DataBase Reference)
• NIST Chemistry Reference: trans-2,6-Dimethylpiperidin-4-one,N-BOCprotected(184368-70-5)
• EPA Substance Registry System: trans-2,6-Dimethylpiperidin-4-one,N-BOCprotected(184368-70-5)

Safety Data

• Hazardous Substances Data: 184368-70-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
trans-2,6-Dimethylpiperidin-4-one,N-BOCprotected is used as a reagent in the preparation of some methylated analogs of isoguvacine derivatives, which are potential GABAA agonists. GABAA agonists are important in the treatment of various neurological disorders, such as anxiety, epilepsy, and insomnia, due to their ability to modulate the activity of the GABAA receptor.
Used in Organic Synthesis:
In the field of organic synthesis, trans-2,6-Dimethylpiperidin-4-one,N-BOCprotected can be employed as a building block or intermediate for the synthesis of more complex organic compounds. Its unique structure and functional groups make it a valuable component in the development of new pharmaceuticals, agrochemicals, and other specialty chemicals.

Upstream product

• 126503-27-3 trans-N-Boc-7,9-dimethyl-1,4-dioxa-8-azaspiro<4.5>decane 
• 126503-08-0 N-Boc-7-methyl-1,4-dioxa-8-azaspiro<4.5>decane 
• 24424-99-5 di-tert-butyl dicarbonate 
• 13200-35-6 (2S,6R)-2,6-dimethylpiperidin-4-one 
• 198211-15-3 (2R,6S)-1-benzyl-2,6-dimethylpiperidin-4-one 
• 32941-09-6 1-benzyl-2,6-dimethylpiperidin-4-one 
• 45717-87-1 2,6-dimethylpiperidin-4-one 
• 1005397-62-5 2,6-dimethylpiperidin-4-one hydrochloride 

Downstream Products

• 1005397-65-8 tert-butyl 2,6-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydropyridine-1(2H)-carboxylate 
• 146337-39-5 tert-butyl (2S,6R)-4-hydroxy-2,6-dimethyl-piperidine-1-carboxylate 
• 146337-39-5 trans-N-Boc-2,6-dimethylpiperidin-4-ol 

Relevant articles and documents

4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-3,6-DIHYDROPYRIDINE-1-(2H)-CARBOXAMIDE DERIVATIVES AS LIMK AND/OR ROCK KINASES INHIBITORS FOR USE IN THE TREATMENT OF CANCER

The present invention concerns a compound of formula (I), in particular as LIMK and/or ROCK kinases inhibitors. The present invention also concerns these new inhibitors for use for the treatment of a condition selected in the group consisting of: cancers, virion infections, ocular hypertension and glaucoma formation, Neurofibromatosis type 1 and 2, psoriatic lesions, inflammatory diseases and hyperalgesia, central sensitization and chronic pain, reproduction erectile dysfunction, and neuronal diseases. The present description discloses the syntheses and characterisation of exemplary compounds as well as pharmacological data thereof (e.g. pages 32 to 127; examples 1 to 96; families 1 to 8; compounds; biological studies; tables). An exemplary compound is e.g. 4-(5-m ethyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-N-phenyl-3,6-dihydropyridine-1-(2H)-carboxamide (example 1; compound 5).

3-(1-OXO-5-(PIPERIDIN-4-YL)ISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF

The present disclosure provides a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein R1, R2, R3, Rx, and n are as defined herein, and methods of making and using same.

AMINOPYRIMIDINES AS ALK INHIBITORS

The present disclosure provides compounds represented by Formula (I): and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R1a, R1b, R2a, R2b, R3, R4, R5, R6, and R7 are as defined as set forth in the specification. The present disclosure also provides compounds of Formula (I) for use to treat a condition or disorder responsive to inhibition of ALK such as cancer.

5,6-DIHYDRO-11H-INDOLO[2,3-B]QUINOLIN-11-ONES AS ALK INHIBITORS

The present disclosure provides compounds represented by Formula( I), and the pharmaceutically acceptable salts and solvates thereof, wherein R1a, R1b, R2a, R2b, R3, R4, R5, R6, R7, E and (B) are as defined as set forth in the specification. The present disclosure also provides compounds of Formula ( I) for use to treat a condition or disorder responsive to inhibition of ALK such as cancer.

COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY

The present invention provides novel compounds of Formulas (I) and (II) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases, e.g., cancers (e.g., breast cancer, prostate cancer, lymphoma, lung cancer, pancreatic cancer, ovarian cancer, neuroblastoma, or colorectal cancer), benign neoplasms, angio genesis, inflammatory diseases, fibrosis (e.g., polycystic kidney disease), autoinflammatory diseases, and autoimmune diseases in a subject.

SPIRO[CYCLOBUTANE-1,3'-INDOLIN]-2'-ONE DERIVATIVES AS BROMODOMAIN INHIBITORS

The present invention provides novel spiro[cyclobutane-1,3'-indolin]-2'- derivatives of formula (I) in which Cy R1, R2, R4, L and 'm' are have the meaning given in the specification, and pharmaceutically acceptable salts thereof. The compounds of formula (I) are useful as bromodomain inhibitors in the treatment or prevention of diseases or disorders where bromodomain inhibition is desired.

Novel kinase inhibitors

The present invention relates to a novel kinase inhibitor useful as a medicine for tumor, nerve disorder and mental illness. The purpose of the present invention is to provide a compound having improved blood-aqueous barrier penetrability to neurodegenerative diseases that cancer spreads to brain or progresses in brain. To this end, provided is a compound represented by chemical formula 1 or a pharmaceutically allowable salt thereof.COPYRIGHT KIPO 2017

TRPA1 MODULATORS

This disclosure relates to polycyclic heteroaromatic compounds useful as TRPA1 modulators, as well as compositions and methods of treating pain that include the compounds.

ORGANIC COMPOUNDS

The present invention provides a compound of formula (I): wherein the variants R1, R2, R3, R4, R5, R6, R7 are as defined herein, and wherein said compound is an inhibitor of CETP, and thus can be employed for the treatment of a disorder or disease mediated by CETP or responsive to the inhibition of CETP.

UROTENSIN II RECEPTOR ANTAGONISTS

The invention is directed to Urotensin II receptor antagonists. More specifically, the present invention relates to certain novel compounds and methods for preparing compounds, compositions, intermediates and derivatives thereof. Pharmaceutical compositio